brain-disorders
(2)
Blue Oak Pharmaceuticals
Blue Oak Pharmaceuticals is a Waltham, Massachusetts biotech founded in 2016 to discover the next generation of drugs for brain disorders. Led by neurobiologist and former Eli Lilly and Sunovion executive Tom Large, the company designs novel, CNS-focused 'privileged chemotypes' and pairs them with systems-neurobiology behavioral assays and AI to hunt first-in-class small molecules for schizophrenia, bipolar disorder and treatment-resistant depression. Its work runs through partnerships with phenotypic-screening firm PsychoGenics and AI drug-design company Exscientia.
Neural Galaxy
Neural Galaxy (also operating as Galaxy Brain Scientific) is a Beijing-based brain science company building a precision, non-invasive neuromodulation platform. Its proprietary personalized Brain Functional Sectors (pBFS) technology maps over 200 functional regions of an individual brain, then guides targeted transcranial magnetic stimulation with millimeter accuracy. Founded in 2019 by Harvard and MIT neuroscientists with serial entrepreneur Coach Wei, the company is running clinical and registration trials across depression, Parkinson's, Alzheimer's, autism and aphasia, and has raised roughly $93M to date.